FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

gton, D.C. 20549		OMB ADDDOVAL

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

	Check this box if no longer subject to
١	Section 16. Form 4 or Form 5
J	Section 16. Form 4 or Form 5 obligations may continue. See
	Instruction 1/h)

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

	nd Address of i Danish	Reporting Person*				er Name <b>and</b> Stance He					т]		heck all	applicab Director	le)	Person	10% Own	ner
(Last) (First) (Middle) C/O LIFESTANCE HEALTH GROUP, INC. 4800 N. SCOTTSDALE ROAD, SUITE 6000					3. Date of Earliest Transaction (Month/Day/Year) 09/07/2022							X Officer (give title Other (specify below)  See Remarks						
(Street) SCOTTS (City)		NZ State)	85251 (Zip)		4. If Amendment, Date of Original Filed (Month/Day/Year)							6.	Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person  Form filed by More than One Reporting Person					
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
Date				2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Instr.		ies Acquir Of (D) (Ins	quired (A) or (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Ow Following Reported		Form:	Direct Indirect Etr. 4)	'. Nature of ndirect Beneficial Ownership			
					Code V Amount (A) or Pri				Price	Tr	Transaction(s) (Instr. 3 and 4)			"	nstr. 4)			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned  (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		nsaction Derivative			6. Date Exercisable and Expiration Date (Month/Day/Year)  7. Title and Amo Securities Under Derivative Secur (Instr. 3 and 4)				s Underlyin e Security	rlying Derivative		9. Number of derivative Securities Beneficially Owned Following Reported		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisal		Expiration Date	Title	Amount of Number of Shares			Transact (Instr. 4)			
Stock Option (right to buy)	\$7.61	09/07/2022		A		2,821,362 <sup>(1)</sup>		(2)		09/07/2032	Common Stock	2,821,3	62	\$0.00	2,821,	362	D	

## **Explanation of Responses:**

- 1. The options were granted by the Issuer pursuant to the LifeStance Health Group, Inc. 2021 Equity Incentive Plan.
- 2. Includes an option to purchase 940,454 shares of the Issuer's common stock, subject to time-based vesting (the "Time-Vesting Option"). The Time-Vesting Option vests as to 25% on each of the first four anniversaries of the vesting commencement date, September 7, 2022. Includes an option to purchase 1,880,908 shares of the Issuer's common stock, subject to time- and performance-based vesting (the "Performance-Vesting Option"). The Performance-Vesting Option vests as to up to 25% on each of the first four anniversaries of the vesting commencement date, September 7, 2022. Following each anniversary of the vesting commencement date, any portion of the Performance-Vesting Option eligible to vest as of such measurement date that did not vest pursuant to the performance-based vesting criteria will be eligible to vest on a quarterly basis thereafter, subject to the same performance-based vesting criteria.

## Remarks:

President and Chief Operating Officer

/s/ Ryan Pardo, as attorney-in-09/09/2022 fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.